GB1098151A - Membrane penetrant compositions comprising dialkyl sulfoxides - Google Patents
Membrane penetrant compositions comprising dialkyl sulfoxidesInfo
- Publication number
- GB1098151A GB1098151A GB4320964A GB4320964A GB1098151A GB 1098151 A GB1098151 A GB 1098151A GB 4320964 A GB4320964 A GB 4320964A GB 4320964 A GB4320964 A GB 4320964A GB 1098151 A GB1098151 A GB 1098151A
- Authority
- GB
- United Kingdom
- Prior art keywords
- agent
- histamine
- specified
- sodium
- anaesthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Pharmaceutical preparations comprise a dialkyl sulphoxide in which each alkyl group contains up to 4 carbon atoms and an effective amount of an antibacterial substance, insulin, a vitamin, a steroid, a cytotoxic agent, an antigen, a neuropharmacological agent, a radiopaque agent, a diagnostic dye, histamine, heparin, a general anaesthetic, a local anaesthetic, an analgesic, or an anti-histamine. The preferred dialkyl sulphoxide is dimethyl sulphoxide. The preparations may contain a pharmaceutically acceptable carrier and may be in the form of a solution, cream, ointment, or suppository. Conventional excipients, e.g. surfactants, buffers or gelling agents, may also be included. The antibacterial substance may be iodine, penicillin or sodium sulfadiazine. A specified steroid is dexamethasone 21-phosphate. Specified cytotoxic agents are methotrexate and thio-TEPA. The antigen may be an allergenic extract of tree pollen. The neuropharmacological agent may be aminophylline. The diagnostic dye may be Evans Blue dye. The general anaesthetic may be sodium pentobarbital. The local anaesthetic may be procaine, or lidocaine. A specified analgesic is sodium salicylate. The anti-histamine may be diphenhydramine hydrochloride. The exemplified vitamin is nicotinic acid. The exemplified radiopaque agent is iodine in aqueous sodium iodide solution.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32915163A | 1963-12-09 | 1963-12-09 | |
US32890863A | 1963-12-09 | 1963-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1098151A true GB1098151A (en) | 1968-01-10 |
Family
ID=26986565
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB4320964A Expired GB1098151A (en) | 1963-12-09 | 1964-12-08 | Membrane penetrant compositions comprising dialkyl sulfoxides |
GB3997867A Expired GB1106170A (en) | 1963-12-09 | 1964-12-08 | Introduction of physiologically active substances into animal tissues |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB3997867A Expired GB1106170A (en) | 1963-12-09 | 1964-12-08 | Introduction of physiologically active substances into animal tissues |
Country Status (5)
Country | Link |
---|---|
BR (1) | BR6465159D0 (en) |
ES (1) | ES306377A1 (en) |
GB (2) | GB1098151A (en) |
IL (1) | IL22493A (en) |
NL (1) | NL140731B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2282263A1 (en) * | 1974-08-23 | 1976-03-19 | Fisons Ltd | NEW SEDATIVE COMPOSITIONS |
GB2119248A (en) * | 1982-04-28 | 1983-11-16 | John Kenneth Mcmullen | Insulin formulations and method of producing them |
EP0189861A2 (en) * | 1985-01-26 | 1986-08-06 | Showa Denko Kabushiki Kaisha | Percutaneous absorption accelerator for ionic water-soluble medicine |
WO1998000158A1 (en) * | 1996-07-03 | 1998-01-08 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
AU775395B2 (en) * | 1996-07-03 | 2004-07-29 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
-
1964
- 1964-11-23 IL IL2249364A patent/IL22493A/en unknown
- 1964-11-25 ES ES0306377A patent/ES306377A1/en not_active Expired
- 1964-12-08 GB GB4320964A patent/GB1098151A/en not_active Expired
- 1964-12-08 GB GB3997867A patent/GB1106170A/en not_active Expired
- 1964-12-09 BR BR16515964A patent/BR6465159D0/en unknown
- 1964-12-09 NL NL6414293A patent/NL140731B/en not_active IP Right Cessation
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2282263A1 (en) * | 1974-08-23 | 1976-03-19 | Fisons Ltd | NEW SEDATIVE COMPOSITIONS |
GB2119248A (en) * | 1982-04-28 | 1983-11-16 | John Kenneth Mcmullen | Insulin formulations and method of producing them |
EP0189861A2 (en) * | 1985-01-26 | 1986-08-06 | Showa Denko Kabushiki Kaisha | Percutaneous absorption accelerator for ionic water-soluble medicine |
EP0189861A3 (en) * | 1985-01-26 | 1988-02-17 | Showa Denko Kabushiki Kaisha | Percutaneous absorption accelerator for ionic water-soluble medicine |
WO1998000158A1 (en) * | 1996-07-03 | 1998-01-08 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US5932547A (en) * | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US6124261A (en) * | 1996-07-03 | 2000-09-26 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US6235712B1 (en) | 1996-07-03 | 2001-05-22 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
AU739169B2 (en) * | 1996-07-03 | 2001-10-04 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
AU775395B2 (en) * | 1996-07-03 | 2004-07-29 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
CZ299464B6 (en) * | 1996-07-03 | 2008-08-06 | Alza Corporation | Implantable drug delivery system, process for its preparation and use of peptide compound formulation |
CZ300378B6 (en) * | 1996-07-03 | 2009-05-06 | Alza Corporation | Stable non-aqueous formulation of a peptide compound and method for preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
BR6465159D0 (en) | 1973-08-02 |
ES306377A1 (en) | 1965-05-01 |
NL6414293A (en) | 1965-06-10 |
IL22493A (en) | 1968-10-24 |
GB1106170A (en) | 1968-03-13 |
NL140731B (en) | 1974-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1405088A (en) | Slow release formulation | |
NL194165B (en) | Carbostyril derivatives, methods of preparation thereof and pharmaceutical compositions containing these derivatives. Derivatives of quinolonyl-2-aminocarboxylic acids and pharmaceutical preparations containing these derivatives. | |
SE8504945L (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTRACYCLING GYCOSIDES | |
US3070499A (en) | Parenteral aqueous solutions of fat soluble vitamins | |
IT1062053B (en) | PHARMACEUTICALLY ACTIVE AMMINOGUANIDINE PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT COMMENGOMO | |
GB1098151A (en) | Membrane penetrant compositions comprising dialkyl sulfoxides | |
GB1317184A (en) | Steroid-containing pharmaceutical preparations | |
EP0230264B1 (en) | Pharmaceutical composition for nasal application, process for its preparation and its use | |
GB1115893A (en) | Pharmaceutical anti-allergic compositions | |
GB2109231A (en) | Medicament containing progesterone | |
US1928346A (en) | Anaesthetic | |
EG10508A (en) | Method for preparation of 5-aryl 2,3-dihydro-2,2(or 3,3)dimethyl-5h-imidazo(2,1-a)isoindol-5-ols and 2(4,4(5,5)dimethyl-2-imidazolin-2-yl)bensophenone acid addition salts used as autidepressant drug | |
US3526698A (en) | Stabilization of levo-3-(3,4-dihydroxyphenyl)-2-methylalanine with sodium bisulfite and sorbitol | |
GB1081551A (en) | Injectable oil compositions | |
GB1359226A (en) | Propylene carbonate medicament base composition | |
GB1133800A (en) | Pharmaceutical compositions | |
JPH1135489A (en) | Solution preventing decomposition of polyoxyethylene hardened castor oils | |
DE2013039A1 (en) | Medicinal tablet for oral administration | |
DE3065087D1 (en) | Piperidine derivatives of 3-hydroxy-thiophene-2-carboxylic acid esters, their preparation, and pharmaceutical preparations containing them | |
EP0056681A2 (en) | Levonantradol and N-methyllevonantradol formulations | |
Swyer | Progestogens and their clinical uses: Part I | |
GB1077039A (en) | A choline derivative and therapeutic compositions containing it | |
ES342394A1 (en) | Novel Benzylaminoimidazoline Derivatives, the preparation thereof and Compositions containing the same | |
GB1246315A (en) | Pharmaceutical compositions | |
GB1200940A (en) | A method for solubilising enduracidin and aqueous solutions thereof |